

キーワード索引

第74巻 平成16年度

| A | |
|----------------------------------|---|
| ACTH | (9・10) 572, 598, 599 |
| ACTH loaded adrenal venous | |
| sampling (AVS) | (9・10) 580 |
| ACTH stimulation | (9・10) 559 |
| ACTH-loading | (9・10) 576 |
| ACTH-stimulated adrenal venous | |
| sampling | (9・10) 596 |
| acute stenosis | (5) 280 |
| adenovirus | (12) 673 |
| adjustment disorder | (2) 75 |
| adjuvant chemo-radiotherapy | (6・7) 329 |
| adosterol scintigraphy | (9・10) 591 |
| adrenal adenoma | (9・10) 564 |
| adrenal disease | (9・10) 596 |
| adrenal primary aldosteronism | |
| (APA) | (9・10) 580 |
| adrenal tumor | (9・10) 576 |
| adrenal venous sampling | (9・10) 572, 576, 585, 588, 591, 598, 599 |
| adult thoracic spine | (8) 359 |
| advanced glycation end-product | |
| (AGE) | (12) 667 |
| aging of injuries | (2) 55 |
| agranulocytosis | (1) 16 |
| aldosterone | (9・10) 564 |
| alpha-fetoprotein producing | |
| gastric carcinoma | (5) 285 |
| Amadori compound | (12) 667 |
| amino-carbonyl reaction | (12) 667 |
| ampula cardiomyopathy | (4) 201 |
| anaplastic large cell lymphoma | (8) 339 |
| anemia | (2) 85 |
| angiotensin converting enzyme | |
| inhibitor (ACEI) | (12) 698 |
| anorexia nervosa | (4) 201 |
| antagonism | (12) 657 |
| antithyroid drug | (1) 16 |
| aortic valve replacement | (3) 179 |
| apoptosis | (6・7) 314, (8) 339, (12) 690 |
| arterio- and arteriolo-sclerosis | (11) 632 |
| arteriosclerosis | (6・7) 305 |
| arteriovenous malformation | (1) 10 |
| arteriovenous malformation (AVM) | (1) 4 |
| astrobiology | (9・10) 525 |
| autoimmune hepatitis | (4) 197 |

| B | |
|---------------------------------|------------|
| bacterial superantigen | (3) 147 |
| belladonna | (9・10) 517 |
| bone matrix protein | (3) 119 |
| bone metabolic marker | (5) 272 |
| bone mineral density | (11) 625 |
| borderline personality disorder | (2) 75 |

C

| | |
|--|-----------------|
| Ca ²⁺ sensitivity | (1) 39 |
| Ca ²⁺ -channel blocker | (1) 39 |
| calcified aorta | (3) 179 |
| calcium | (11) 650 |
| cancer immunotherapy | (6・7) 291 |
| cancer vaccine | (6・7) 291 |
| capsaicin | (11) 609 |
| carbon monoxide poisoning | (11) 609 |
| carcinoma in situ of the pancreas | (8) 350 |
| cardiomyocyte | (1) 33 |
| cases of malpractice | (2) 102 |
| catheterization | (9・10) 588 |
| cause-effect relationship | (2) 68 |
| CD2 associated protein | (12) 690 |
| CD30 | (8) 339 |
| CD4 ⁺ CD45RA ⁺ T cells | (3) 147 |
| CD4 ⁺ CD45RO ⁺ T cells | (3) 147 |
| cDNA array | (9・10) 545 |
| cell proliferation | (12) 690 |
| cell therapy | (6・7) 291 |
| cerebral aneurysm | (1) 10 |
| 16 channel MDCT | (9・10) 598 |
| chemical terrorism | (11) 609 |
| child abuse | (2) 55 |
| children | (9・10) 545, 552 |
| chronic myeloid leukemia | (9・10) 511 |
| chronic renal failure | (9・10) 552 |
| chronic sinusitis | (11) 619 |
| Cl | (1) 33 |
| clinical governance | (4) 223 |
| Code of Criminal Procedure | (2) 102 |
| cognitive impairment | (2) 85 |
| collecting duct | (12) 673 |
| conformity | (4) 208 |
| continuous quality improvement | |
| (CQI) | (4) 208 |

coronary artery disease (3) 140
 corticosteroid (6·7) 305
 cortisol (9·10) 564
 cost effectiveness (4) 217
 creatine kinase (4) 201
 creatinine (5) 256, (6·7) 305
 critical pass (9·10) 596
 CT (9·10) 588
 CTL (6·7) 291
 cystatin C (5) 256
 cytokines (9·10) 545

D

dendritic cell (6·7) 291
 detoxication (12) 657
 DHP (direct hemoperfusion) (12) 657
 diabetes mellitus (3) 157, (11) 625
 diabetic nephropathy (4) 190
 diagnosis (9·10) 572
 dialysis (9·10) 552
 DNA polymorphisms (3) 133

E

E-cadherin (1) 26
 early neonata (2) 94
 EGFR (5) 243
 Eigorotta Yamachicchi Stent (5) 280
 elderly patient (2) 85
 end-stage renal disease (4) 190
 endarterectomy (3) 179
 endoscopic sinus surgery (11) 619
 endovascular treatment (1) 1, 10
 enteroenteric magnetic compression
 anastomosis (5) 280
 eosinophilic granuloma (8) 359
 erk (5) 264
 estrogen deficiency (3) 126
 estrogen receptor (3) 126
 executive manager (6·7) 300
 experimental dog model (5) 280
 extended lymphadenectomy (6·7) 329

F

1/f fluctuations (2) 94
 foodpoisoning (12) 657
 free jejunal transplantation (6·7) 329
 fulminant hepatic failure (11) 642
 furaPE3/AM (1) 39

G

gamma knife (1) 4
 gammaknife surgery (1) 1
 gastric cancer (6·7) 325, (8) 354
 gefitinib (5) 243
 gene conversion (3) 167
 geomagnetic disturbance (9·10) 525
 giant arteriovenous malformation (1) 1
 glomerular filtration rate (4) 190, (5) 256
 glucocorticoid-induced osteoporosis (5) 272
 glycated protein (12) 667
 goblet cell hyperplasia (5) 248
 Graves' disease (1) 16

H

Hashimoto's thyroiditis (1) 16
 heart rate variability (9·10) 525
 heartbeat variability (2) 94
 hemodialysis (2) 85, (11) 625
 hemp (9·10) 517
 hepatic metastases (1) 26
 high-glucose (5) 264
 HNF-1 α (3) 157
 hospital evaluation (4) 213
 hospital management (4) 217
 hospital safety management (4) 213
 hospitality (4) 223
 5HT_{2A} receptor antagonists (3) 140
 hydrogen peroxide (12) 673
 18-hydroxycortisol (9·10) 591
 hyperphosphatemia (3) 119
 hypertension (9·10) 576
 hypoglycemia (4) 201

I

IgA nephropathy (5) 256,
 (6·7) 305, (11) 632
 IL-13 (5) 248
 Imatinib (9·10) 511
 immunostaining (11) 642
 inducible nitric oxide synthase (11) 642
 infant of diabetes mother (3) 157
 informed consent of the deceased (2) 102
 infusion and drug delivery system (4) 213
 inhibitors of the renin-angiotensin
 system (11) 632
 initiation of dialysis (4) 190
 intensity modulated radiation

therapy (IMRT) (4) 183
interleukin-8 (8) 339
intoxication (9·10) 517
involutional osteoporosis (5) 272
ischemia (1) 33
ischemic cerebrovascular disease (1) 10
ischemic-reperfusion renal injury (6·7) 314
ISO9001 (4) 217

J

judicial autopsy (2) 102

K

K201 (JTV519) (1) 39
klotho (6·7) 314, (12) 673

L

large neck aneurysm (1) 1
less invasive surgery (1) 10
line and staff (6·7) 300
living-related renal transplantation (2) 75
localized narrowing of
the pancreatic duct (8) 350

M

Maillard reaction (12) 667
matrix metalloproteinase (MMP)-2 (1) 26
matrix metalloproteinase (MMP)-9 (1) 26
medical negligence (2) 68
medico-legal court case (2) 68
membranous lupus nephritis (12) 680
methamphetamine (9·10) 517
micro-catheter (9·10) 598
microsurgery (1) 1
mini-thoracotomy (6·7) 329
minimal change nephrotic syndrome (9·10) 545
MODY (3) 157
molecular target medicine (4) 183
molecular target therapy (5) 243
mood states (2) 85
mortality (4) 190
mucin (5) 248
mucociliary clearance (5) 248
multi-slice spiral computed
tomography (11) 650
myelolipoma (9·10) 580

N

nephrotic syndrome (12) 680
nitric oxide (11) 642
nuclear factor kappa B (8) 339

O

organization chart (6·7) 300
organizational change (6·7) 300
osteoprotegerin (11) 625
ostiomeatal complex (11) 619
oxidative stress (12) 673

P

p38 (5) 264
paclitaxel (8) 354
painless thyroiditis (1) 16
PAM (2-pyridine aldoxime methiodine) (12) 657
pancreatitis associated with pancreatic
cancer (8) 350
parathyroid hormone (11) 625
paternity testing (3) 133
patient safety (4) 223
percutaneous old balloon angioplasty (3) 140
pericholangitis (4) 197
peritoneal fibrosis (5) 264
peritoneal metastasis (8) 354
PKC (1) 33
poisoning (9·10) 517
porcelain aorta (3) 179
portal venous tumor thrombosis (5) 285
posture test (9·10) 591
pre-B lymphocyte (3) 126
preclinical Cushing's syndrome (9·10) 564
primary aldosteronism (9·10) 559, 564, 569,
572, 576, 585, 598, 599
primary biliary cirrhosis (4) 197
primary sclerosing cholangitis (4) 197
probability of paternity (3) 133
prognosis (12) 698
proteinuria (6·7) 305, (12) 680

Q

QMS (4) 217
quality control (4) 217
quality control (QC) (4) 208
quality management (4) 223

R

| | | |
|-----------------------------------|--------|-----|
| R-R interval histogram | (2) | 94 |
| radiosurgery | (1) | 4 |
| rat peritoneal mesothelial cells | (5) | 264 |
| recipient | (2) | 75 |
| rectal cancer | (6·7) | 321 |
| rectovaginal fistula | (6·7) | 321 |
| renal dialysis | (11) | 650 |
| renal dysfunction | (9·10) | 572 |
| renal ischemia reperfusion injury | (12) | 690 |
| renal transplantation | (9·10) | 552 |
| requirements | (4) | 208 |
| respiration | (2) | 94 |
| right of expectation | (2) | 68 |
| risk management | (4) | 213 |
| risk manager | (6·7) | 300 |

S

| | | |
|---|--------|----------|
| S-1 | (8) | 354 |
| selective adrenal venous sampling | (9·10) | 559, 569 |
| selective estrogen receptor modulator (SERM) | (3) | 126 |
| sentinel node | (6·7) | 325 |
| serum potassium | (12) | 698 |
| short-term S-Cr change | (12) | 698 |
| SMA | (3) | 167 |
| SMN gene | (3) | 167 |
| smooth muscle | (1) | 39 |
| sodium-dependent phosphate co-transporter | (3) | 119 |

| | | |
|--------------------------------------|-------|-----|
| splenic hemangiomas | (1) | 47 |
| sputum | (5) | 248 |
| stereotactic radiation surgery (SRS) | (4) | 183 |
| stereotactic radiation therapy (SRT) | (4) | 183 |
| suicide | (11) | 609 |
| superficial esophageal carcinoma | (6·7) | 329 |
| surgery | (6·7) | 325 |
| sustainability | (4) | 223 |
| systemic lupus erythematosus | (12) | 680 |

T

| | | |
|--------------------------------|-------|-----|
| tailor maid radiotherapy | (4) | 183 |
| takotsubo-like cardiomyopathy | (4) | 201 |
| Th1 | (3) | 147 |
| Th2 | (3) | 147 |
| total quality management (TQM) | (4) | 208 |
| transvaginal closure | (6·7) | 321 |
| tyrosine kinase inhibitor | (5) | 243 |

U

| | | |
|--|--------|-----|
| unilateral multiple adrenocortical micronodules | (9·10) | 569 |
| unnatural death | (2) | 102 |
| urinary protein excretion | (11) | 632 |

V

| | | |
|--------------------------------|---------------|-----|
| vascular calcification | (3) 119, (11) | 650 |
| veno-occlusive disease | (4) | 197 |
| vertebral compression fracture | (5) | 272 |
| vitamin D | (11) | 650 |
| volume | (1) | 33 |